<DOC>
	<DOCNO>NCT00637338</DOCNO>
	<brief_summary>PF-04603629 investigate treatment Type 2 diabetes mellitus ( T2DM ) . Specifically , PF-04603629 protein combination exendin-4 ( glucagon-like peptide-1 ( GLP-1 ) mimetic currently market Byetta® ) fuse human transferrin ( naturally occur protein ) order increase concentration exendin-4 blood . The purpose study characterize safety , tolerability , pharmacokinetics , pharmacodynamics PF-04603629 follow multiple escalate subcutaneous dos adult subject T2DM .</brief_summary>
	<brief_title>Multiple Dose Escalation Trial Of PF-04603629 Given To Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>B0571002 terminate August 19 2008 due decision discontinue development PF-04603629 observing ( B0571001 B0571002 ) trend reversible increase heart rate within normal range , occur efficacious dos . Thus , compound primarily terminate due safety concern , although immediate safety risk subject study .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Patients type 2 diabetes mellitus take treatment take metformin ( change treatment , include dose , past 2 month ) . Subjects previously treat sulfonylurea combination metformin may eligible switched metformin minimum 4 week dose . Male and/or female subject ( female woman nonchildbearing potential ) age 18 70 year , inclusive . Body Mass Index ( BMI ) approximately 22 40 kg/m2 Fasting Cpeptide test result must &gt; 0.4 nmol/L . HbA1c ≥7 % ≤11 % . If subject require washed sulfonylurea , HbA1c limit ≥7 % ≤9.5 % . Screening fast blood glucose , ≤60 ≥270 mg/dL . One repeat screen fast blood glucose allow . Previous treatment approve investigational GLP1 mimetic . Have know allergy yeast , yeastderived yeast containing product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>Long-acting GLP-1 Diabetes</keyword>
</DOC>